<DOC>
	<DOCNO>NCT02509507</DOCNO>
	<brief_summary>This phase 1 , multicenter , open-label trial evaluate safety talimogene laherparepvec , inject intrahepatically , liver tumor know progression subject Hepatocellular carcinoma subject liver metastasis breast adenocarcinoma , colorectal adenocarcinoma , gastroesophageal cancer ( adenocarcinoma squamous cell carcinoma ) , melanoma , non-small cell lung cancer , clear cell renal cell carcinoma . The study consist 2 part 2 group . Part 1 3+3 dose escalation consist 3 sequential dose cohort administer talimogene laherparepvec increase dose concentration dose volume . In Part 1 , Maximum Tolerated Dose determination non-hepatocellular carcinoma liver metastasis ( Group A ) evaluate separately hepatocellular carcinoma ( Group B ) , dose cohort need deem safe non-hepatocellular carcinoma subject administer hepatocellular carcinoma subject . Part 2 consist expansion cohort administer Maximum Tolerated Dose talimogene laherparepvec determine Part 1 Groups A ( non-hepatocellular carcinoma ) B ( hepatocellular carcinoma ) approximately 10 subject tumor type .</brief_summary>
	<brief_title>Safety Study Talimogene Laheraprepvec Injected Into Hepatocellular Carcinoma Metastatic Liver Tumors</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<criteria>Subjects must histologically confirm breast adenocarcinoma , colorectal adenocarcinoma , gastroesophageal cancer ( adenocarcinoma squamous cell carcinoma ) , melanoma , nonsmall cell lung cancer , clear cell renal cell carcinoma liver metastases hepatocellular carcinoma know disease progression . Nonhepatocellular carcinoma subject must receive least 1 prior standard care systemic anticancer therapy metastatic disease . Subjects must measurable liver tumor suitable injection . Eastern Cooperative Oncology Group performance status must 0 1 , life expectancy approximately 5 month . Adequate hematological , renal , hepatic coagulation function require . ChildPugh score must A B7 . Subjects must candidate hepatic surgery locoregional therapy liver tumor curative intent plan systemic anticancer therapy . Liver tumor must estimate invade approximately onethird liver . Liver tumordirected therapy , hepatic surgery , antibodybased therapy , immunotherapy must perform &lt; 28 day , chemotherapy &lt; 21 day , target small molecule therapy hormonal therapy &lt; 14 day prior enrollment . Subjects must either central nervous system metastasis irradiate , stable cerebral metastasis breast adenocarcinoma , nonsmall cell lung cancer , clear cell renal cell carcinoma , melanoma . Subjects must history evidence symptomatic autoimmune pneumonitis , glomerulonephritis , vasculitis , symptomatic autoimmune disease . Subjects must symptomatic autoimmune disease immunosuppressed . Subjects must history solid organ transplantation . For nonhepatocellular carcinoma , must acute chronic hepatitis B virus hepatitis C virus infection . For hepatocellular carcinoma , hepatitis B virus hepatitis C virus viral load must undetectable , must recent treatment certain antiviral medication . There macroscopic intravascular invasion tumor main portal vein , hepatic vein , vena cava . Subjects must active herpetic skin lesion prior complication herpetic infection ( eg , herpetic keratitis encephalitis ) must require treatment antiherpetic drug . Subjects must require concomitant treatment warfarin . Female subject childbearing potential unwilling use acceptable method ( ) effective contraception protocol treatment 3 month last dose talimogene laherparepvec .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Liver tumour</keyword>
</DOC>